ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2020
COVID-19 and sickle cell disease in Bahrain.
Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Impact of the SARS-CoV-2 infection in individuals with sickle cell disease: an integrative review.Frontiers in medicine · 2023Pooled it
- Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: Update of a living systematic review and meta-analysis.PLoS medicine · 2022Pooled it
- Trends in CT pulmonary angiography utilization and recurrent imaging in sickle cell disease: a longitudinal study.International journal of emergency medicine · 2025Article
- A Comprehensive Study on the Hematological Progression of Sickle Cell Disease Patients with COVID-19 at the Center for Research and Control of Sickle Cell Disease, Bamako.Journal of blood research & hematologic diseases · 2024Article
- Deep venous thrombosis and acute pericarditis associated with severe acute respiratory syndrome coronavirus 2 infection in a Congolese infant with sickle cell disease: a case report.Journal of medical case reports · 2022Article
- Clinical outcomes of COVID-19 in patients with sickle cell disease and sickle cell trait: A critical appraisal of the literature.Blood reviews · 2022Review
- Sickle cell disease and COVID-19 in pregnant women.Journal of gynecology obstetrics and human reproduction · 2022Article
- [SARS-CoV-2 infection in patients with sickle cell disease].Medicina clinica · 2021Article
- SARS-CoV-2 infection in patients with sickle cell disease.Medicina clinica (English ed.) · 2021Article
- Sickle cell disease and COVID-19: Susceptibility and severity.Pediatric blood & cancer · 2021Review
- Comorbidities are risk factors for hospitalization and serious COVID-19 illness in children and adults with sickle cell disease.Blood advances · 2021Article
- Article
- SARS CoV-2 infection in a patient with sickle cell disease - Atypical presentation.Journal of family medicine and primary care · 2021Article
- Coronavirus disease 2019 (COVID-19) in special groups: A single-center experience in sickle cell disease patients in Saudi Arabia.Journal of family & community medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCoronavirus disease 2019 (COVID-19) is caused by a newly identified strain of the coronavirus family that has been shown to affect the hemoglobin beta chain, the same chain that has sickle cell disease (SCD) mutation. This study was undertaken to see if COVID-19 infection increased disease severity in patients with SCD.
methodsMass screening of the Bahraini population was undertaken between February and April 2020.
resultsA total of 38,092 Bahraini people were tested for COVID-19 during this period; 378 (1%) were SCD patients. Six patients with SCD had COVID-19 (1.6%): three remained asymptomatic, two had mild symptoms and one required oxygen therapy. The SCD patients had a similar average length of stay when compared with non-SCD COVID-19 patients (10.7 days).
conclusionThe infection rate, clinical course and viral clearance seen for the SCD patients with COVID-19 were no different to those without SCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.